DOI: https://doi.org/10.18370/2309-4117.2016.27.30-35

Treatment of genital warts: focus on vaginal dysbiosis

И. В. Лахно

Abstract


Bacterial vaginosis is a common companion of human papillomavirus infection. It can also be combined with vaginal candidiasis and tends to recur. Recurrences are due to the presence of commensal vaginal Atopobium vaginae. Bacterial vaginosis is pathogenically associated with the blockade of the inflammatory reaction at the vaginal mucosa level. Therefore it is necessary to use drugs for sanitation with the active ingredient that effects anaerobes, Gardnerella vaginalis, Atopobium vaginae, yeasts, has immunomodulatory properties, does not inhibit the lactobacillus growth and has no cross-resistance with other antibacterial drugs. Myramistin are satisfied all these requirements.

The study of the efficiency of vaginal suppositories with myramistin (drug tamistol) in treatment of patients with genital warts was performed. There were examined 142 women. Group I included 30 healthy women; group II included 55 patients with genital warts (28 participants in IIA subgroup with bacterial vaginosis, 27 patients in IIB subgroup with bacterial vaginosis and chronic recurrent vaginal candidiasis). Group III was included 57 women with genital warts (29 patients with bacterial vaginosis in IIIA subgroup and 28 women with bacterial vaginosis and chronic recurrent vaginal candidiasis in the IIIB subgroup).

Group II patients was performed the chemical destruction of genital warts after rectal use recombinant interferon suppositories for 10 days. Group III patients additionally prescribe a course of the vaginal suppositories tamistol within 10 days.

The results of the study suggest that the use of tamistol suppositories in complex treatment of patients with genital warts increases the effectiveness of remedial measures. Restoration of the vaginal microbial landscape with tamistol reduced the need for chemical destruction sessions of warts and the number of recurrences. The results suggest theoretically justified the use of immunomodulators and sanitation of the vagina in a complex treatment of human papillomavirus infection.


Keywords


human papillomavirus infection; genital warts; vaginal dysbiosis; tamistol

References


Akinbiyi, A.A., Watson, R., Feyi-Waboso, P. “Prevalence of Candida albicans and bacterial vaginosis in asymptomatic pregnant women in South Yorkshire, United Kingdom. Outcome of a prospective study.” Arch Gynecol Obstet 278.5 (2008): 463–66.

Bradshaw, С.S., Tabrizi, S.N., Fairley, С.К., et al. “The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy.” The Journal of infectious diseases 194.6 (2006): 828–36.

Burd, E.M. “Human papillomavirus and cervical cancer.” Clin Micr Rev 16.1 (2003): 1–17.

Diogenes, M.A., Barroso, M.G. “Experiencing pregnancy with human papillomavirus: a case study.” Rev Gaucha Enferm 28.3 (2007): 340–9.

Lacey, C.J. “Therapy for genital human papillomavirus-related disease.” J Clin Virol 32.1 (2005): 82–90.

Quan, M. “Vaginitis: diagnosis and management.” Postgrad Med 122.6 (2010): 117–27.

Ospelnikova, T.P. “Detection of the interferon deficiency in inflammatory gynecological diseases and its correction with interferon inducers.” Georgian Med News 11 (2012): 24–32.

Sherrard, J., Donders, G., White, D., et al. “European (IUSTI/WHO) guideline on the management of vaginal discharge.” Int J STD AIDS 22.8 (2011): 421–29.

Svare, J.A., Schmidt, H., Hansen, B.B., Lose, G. “Bacterial vaginosis in a cohort of Danish pregnant women: prevalence and relationship with preterm delivery, low birthweight and perinatal infections.” BJOG 113.12 (2006): 1419–25.


GOST Style Citations


1. Akinbiyi, A.A., Watson, R., Feyi-Waboso, P. “Prevalence of Candida albicans and bacterial vaginosis in asymptomatic pregnant women in South Yorkshire, United Kingdom. Outcome of a prospective study.” Arch Gynecol Obstet 278.5 (2008): 463–66.

2. Bradshaw, С.S., Tabrizi, S.N., Fairley, С.К., et al. “The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy.” The Journal of infectious diseases 194.6 (2006): 828–36.

3. Burd, E.M. “Human papillomavirus and cervical cancer.” Clin Micr Rev 16.1 (2003): 1–17.

4. Diogenes, M.A., Barroso, M.G. “Experiencing pregnancy with human papillomavirus: a case study.” Rev Gaucha Enferm 28.3 (2007): 340–9.

5. Lacey, C.J. “Therapy for genital human papillomavirus-related disease.” J Clin Virol 32.1 (2005): 82–90.

6. Quan, M. “Vaginitis: diagnosis and management.” Postgrad Med 122.6 (2010): 117–27.

7. Ospelnikova, T.P. “Detection of the interferon deficiency in inflammatory gynecological diseases and its correction with interferon inducers.” Georgian Med News 11 (2012): 24–32.

8. Sherrard, J., Donders, G., White, D., et al. “European (IUSTI/WHO) guideline on the management of vaginal discharge.” Int J STD AIDS 22.8 (2011): 421–29.

9. Svare, J.A., Schmidt, H., Hansen, B.B., Lose, G. “Bacterial vaginosis in a cohort of Danish pregnant women: prevalence and relationship with preterm delivery, low birthweight and perinatal infections.” BJOG 113.12 (2006): 1419–25.





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)